We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

178 hedge funds and large institutions have $539M invested in Meridian Bioscience Inc in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 58 increasing their positions, 54 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

691% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $141K

30% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 23

3% more funds holding

Funds holding: 172178 (+6)

7% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 54

0% less capital invested

Capital invested by funds: $542M → $539M (-$2.5M)

Holders
178
Holders Change
+6
Holders Change %
+3.49%
% of All Funds
4.04%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
30
Increased
58
Reduced
54
Closed
23
Calls
$1.12M
Puts
$141K
Net Calls
+$975K
Net Calls Change
+$866K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$73.8M +$1.42M +97,242 +2%
BCM
2
Brown Capital Management
Maryland
$65.3M -$12.1M -828,323 -15%
Vanguard Group
3
Vanguard Group
Pennsylvania
$58.9M +$2.37M +162,058 +4%
Renaissance Technologies
4
Renaissance Technologies
New York
$31.2M +$2.62M +178,900 +9%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$25M +$569K +38,859 +2%
State Street
6
State Street
Massachusetts
$17.6M +$729K +49,825 +4%
Norges Bank
7
Norges Bank
Norway
$15.9M
Millennium Management
8
Millennium Management
New York
$15.9M +$5.89M +402,430 +55%
New York State Common Retirement Fund
9
New York State Common Retirement Fund
New York
$14.8M -$14.6K -1,000 -0.1%
PP
10
Prudential plc
United Kingdom
$12.9M
SFM
11
Systematic Financial Management
New Jersey
$12.4M +$11.6M +790,508 +810%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$11.1M -$1.14M -77,705 -9%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$9.74M +$1.91M +130,722 +23%
JP Morgan Chase
14
JP Morgan Chase
New York
$8.73M +$9.1M +621,349 +31,350%
Northern Trust
15
Northern Trust
Illinois
$7.64M -$102K -6,958 -1%
Wells Fargo
16
Wells Fargo
California
$7.38M -$1.59M -108,731 -17%
Charles Schwab
17
Charles Schwab
California
$6.6M +$761K +51,976 +12%
Deutsche Bank
18
Deutsche Bank
Germany
$5.9M +$3.28M +224,359 +114%
Morgan Stanley
19
Morgan Stanley
New York
$5.85M +$363K +24,789 +6%
Prudential Financial
20
Prudential Financial
New Jersey
$5.27M +$644K +44,014 +13%
Principal Financial Group
21
Principal Financial Group
Iowa
$4.63M -$20.5K -1,398 -0.4%
Fifth Third Bancorp
22
Fifth Third Bancorp
Ohio
$3.87M
Assenagon Asset Management
23
Assenagon Asset Management
Luxembourg
$3.76M +$3.94M +268,889 New
Ameriprise
24
Ameriprise
Minnesota
$3.66M -$33.8K -2,309 -0.9%
Two Sigma Advisers
25
Two Sigma Advisers
New York
$3.27M +$86.4K +5,900 +3%

VIVO Hedge Fund Activity: Q4 2017 in Review

178 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q4 2017, worth a combined $539M — down 0.46% from $542M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new VIVO positions and 23 closed out — a net gain of 7 holders — while 58 added to existing stakes and 54 trimmed.

The largest buyer was Systematic Financial Management, adding an estimated $11.6M. The largest seller was Brown Capital Management, cutting an estimated $12.1M.

  • 178 institutional investors held Meridian Bioscience Inc (VIVO) as of Q4 2017, up from 172 in Q3 2017.
  • Funds reported $539M of Meridian Bioscience Inc stock for Q4 2017, down 0.46% quarter-over-quarter.
  • 30 funds opened new Meridian Bioscience Inc positions in Q4 2017 and 23 closed out, a net change of +7 holders.
  • The largest Meridian Bioscience Inc buyer in Q4 2017 was Systematic Financial Management, an estimated $11.6M added.
  • The largest Meridian Bioscience Inc seller in Q4 2017 was Brown Capital Management, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2017.